Predictive and prognostic markers in gastrointestinal cancers

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 291-299

  Leichman, Cynthia Gail ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; PROTEIN P53; TUMOR MARKER;

ANGIOGENESIS; CANCER GROWTH; CELL CYCLE; DIGESTIVE SYSTEM CANCER; HUMAN; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; TARGET CELL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTIGENS, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034949569     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00013     Document Type: Review

References (87)

1. Genetic alteration during colorectal-tumor development
2. P53 dependent apoptosis modulates the cytotoxicity of anti-cancer agents
3. p53 in tumor pathology: Can we trust immunohistochemistry? Revisited
4. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
5. p53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients
6. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers
7. p53 and the behavior of colorectal cancer
8. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinoma
9. Evaluation of multiple bio-pathologic factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2
10. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance
11. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer
12. p53 alterations are associated with improved prognosis in distal colonic carcinomas
13. K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma
14. p53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas
15. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy
16. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer
17. p21 is necessary for the p53 mediated G1 arrest in human cancer cells
18. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
19. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study
20. p53 and K-ras mutations in carcinoma of the rectum among Finnish women
21. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer
22. Reappraisal of K-ras and p53 mutations in the recurrence of Dukes' B2 rectal cancer after curative resection
23. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
24. Genetic alterations of sporadic colorectal cancer with microsatellite instability, especially characteristics of multiple colorectal cancers
25. Molecular profiling of sporadic colorectal tumors by microsatellite analysis
26. Population-based molecular detection of hereditary nonpolyposis colorectal cancer
27. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro
28. Regulation of p53 expression by thymidylate synthase
29. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
30. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease free and overall survival in rectal cancer
31. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
32. Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival
33. Immunohistochemical expression of thymidylate synthase as a prognostic factor and as a chemotherapeutic efficacy index in patients with colorectal carcinoma
34. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancers
35. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
36. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil
37. Pyrimidine nucleotide metabolism in human colon carcinomas: Comparison of normal tissues, primary tumors and xenografts
38. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
39. Thymidine phosphorylase is angiogenic and promotes tumor growth
40. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
41. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer
42. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
43. Prognostic value of endothelial growth factor expression in colorectal cancer patients
44. Elevated levels of angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
45. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
46. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathologic factors and tumor markers
47. VEGF, VEGF-B, VEGF-C, and their receptors KDR, FLT-1, and FLT-4, during the neoplastic progression of human colonic mucosa
48. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastases vascularity and volume
49. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical evidence of platelet scavenging?
50. Asssociation of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer
51. Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability
52. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
53. Bcl-2 and the regulation of programed cell death
54. Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo
55. Down-regulation of Bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14:18) chromosomal translocation in fixed tissues
56. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer
57. Protein expression of p53, p21 (waf1/cip1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas
58. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma
59. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion 5-fluorouracil and weekly leucovorin
60. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relation with the clinical response to 5-fluorouracil
61. Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients
62. Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy
63. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil
64. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
65. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins
66. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage
67. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents
68. A histopathologic assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: Relation to apoptotic activity, p53 and bcl-2 expression
69. Effect of mutation and conformation on the function of p53 in colorectal cancer
70. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
71. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
72. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
73. Molecular and prognostic factors in rectal cancer treated by radiation and surgery
74. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma
75. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
76. Prognostic implications of microsatellite genotypes in gastric carcinoma
77. Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis
78. Expressions of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma
79. Microvessel count, proliferating cell nuclear antigen and Ki-67 indices in gastric adenocarcinoma
80. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-erbB2, c-myc and EGFr as prognostic factors in gastric cancer
81. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
82. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers
83. Vascular endothelial growth factor expression predicts outcome and lymph node metastases in squamous cell carcinoma of the esophagus
84. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems
85. Serum level of Her-2/neu in patients with gastric cancer: Correlation with Her-2/neu overexpression in gastric carcinoma tissue
86. p53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus
87. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas